1Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatmentpredictor of sustained virologic response in genotype 1 hepatitis C virus [J]. Gastroenterology,2010,139:120-129,e 18.
2Kao H, Wei L, Lopez-Talavera JC, et al, Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J]. J Gastroenterol Hepatol,2014,29:545-553.
3Liao XW, Ling Y, Li XH, et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Hart population[J]. Antivir Ther,2011,16:141-147.
4Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis[J]. N Engl J Med,2014,370:1973-1982.
5Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype lb infection. Gastroenterology,2014,147:359- 365,el.
6Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for tmtreated HCV genotype 1 infection[J]. N Engl J Med,2014,370:1889- 1898.
7Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection[J]. N Engl J Med,2014,370:1483-1493.
8AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C[S].www.hcvguidelines.org. 2014.
9Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3[R]. N Engl J Med,2014,370:1993-2001.
